Neueste

  • Flow Capital Holdings - Krypto-Assets in der On-Chain-Geschäftswelt zirkulieren lassen

    Die Zahl der institutionellen Investoren (Vermögensverwalter, Stiftungen) mit Krypto-Assets ist dramatisch gestiegen und wird in Zukunft weiter wachsen, so eine neue Umfrage von Fidelity Digital Assets. 70 % der institutionellen Investoren beabsichtigen, in naher Zukunft digitale Assets zu kaufen oder in sie zu investieren, und über 90 % von ihnen wollen dies bis 2026 tun. Mehr als 90 % dieser Ein
  • USA: Rätsel um die Herkunft des Coroanvirus soll endlich geklärt werden

    Das Corona-Virus hält die Welt mittlerweile seit über einem Jahr in dauerhafter Alarmbereitschaft. Mit den ersten bekannten Fällen Ende 2019, erreichte die Verbreitung Ausmaße, die zur aktuellen weltweiten Pandemie geführt haben. Weltweit wird der Ursprung im chinesischen Wuhan gesehen. Aber stimmt das überhaupt? Es kann nicht automatisch davon ausgegangen werden, dass Wuhan auch tatsächlich den U
  • Avalanche Cross-chain DEX Project HurricaneSwap Completes Over $1 Million Financing

    HurricaneSwap, a cross-chain DEX project on Avalanche, received over one million dollars from worldwide capitals including Asia leading ecosystem fund AVATAR and China-based investment firm, LD Capital. This investment will bring HurricaneSwap funding, technology, community, and other resources to support and promote the ecosystem construction and market development of HurricaneSwap.
  • InfiRay Releases World's 1st 8 Micron Thermal Camera Detector

    Yantai, China, June 9, 2021 - (ACN Newswire) - InfiRay has developed the world's 1st 8 micron uncooled thermal camera detector, with a large array (1920 x 1080) and core technologies including a low noise readout circuit, high uniformity VOx film, sub-wavelength optical absorption structure, and small pixel self-heating effect compensation. A higher spatial resolution has been achieved and moving
  • Technology Innovation Drives Future-Oriented Industries--The 5th Future Network Development Conference Opened On June 17th

    On June 8th, the organizing committee of the 5th Future Network Development Conference held a press conference in the Purple Mountain Laboratory. Liu Yunjie, academician of Chinese Academy of Engineering and director of the Purple Mountain Laboratory, and Wang Aijun, deputy director of Jiangning Economic and Technological Development Zone Administrative Committee, attended the press conference to
  • 2021 Geek Review: Top 3 BEST CHEAP Thermal Imaging Camera for Smartphones, FLIR ONE Pro and Seek Lose to InfiRay T3S

    Today I’d like to share a useful tool with you all – Thermal Imaging Camera for Smartphones. During circuit design or troubleshooting, Thermal Imaging Cameras can directly “SEE” the temperature distribution, and it’s easy to find and locate the insufficient heat accumulation and heat dissipation in circuit design. There are not many manufacturers of Smartphone Thermal Cameras on the market. I have
  • Dänemark wird von den USA zur Überwachung eingesetzt, ist es geeignet, einen

    Das der US-Amerikanische Geheimdienst NSA deutsche Spitzenpolitiker wie Kanzlerin Angela Merkel, Frank-Walter Steinmeier und Peer Steinbrück ausgespäht hat, ist seit Jahren bekannt. Bereits 2013 enthüllte Edward Snowden die brisanten Aktionen des US-Geheimdienstes. Diese wurden jedoch bis 2020 nicht ernst genommen. Erst als der dänische Sender DR durch umfangreiche Recherchen über die Spähaktion b
  • Hu Yiying, eine berühmte chinesische Huqin-Spielerin, die den traditionellen Stimmumfang der Huqin

    Zwischen den endlosen Sandhügeln Westasiens dauerten die arabische Musik, die viel Hoffnung und Poetik in sich bergen, seit Jahrtausend. Doch in der Turbulenz des Zeitalters tauchte ihre Mysterien und Glanz kaum auf. Feuer und Rauch des Kriegs, Tränen der Leute, sowie ein Gefühl der Verlassenheit herrschten dieses Gebiet. Jinghu, trotz ihrer hundertjährigen Geschichte, ist ein oft vergessenes Musi
  • BYD Builds One-millionth New Energy Passenger Car

    First 100 pure-electric BYD Tang SUVs head to Norway with plans to deliver 1500 cars in 2021
  • Yol Ayrımındaki Türkiye’ye Tehdit: ‘Sözde Soykırım Kartı’

    Türk Dış politikasındaki değişimin yarattığı deprem her daim ABD’nin Ermeni Soykırımı konusundaki tavrında etkili olmuştur. Sözde Ermeni soykırımı tasarıları 1975 yılından itibaren Amerikan Temsilciler Meclisi’nin neredeyse her döneminde gündeme gelmiştir. Tasarı farklı şekillerde birkaç kez Meclis’te oylanmış, hatta 1975 ve 1984’te Temsilciler Meclisi Genel Kurulu tarafından da kabul edilmiştir.

Link

Bayer and OrigiMed reached a partnership on CDx-IVD development

07-29     OrigiMed


• Bayer and OrigiMed reached a partnership to develop a next-generation sequencing (NGS) based companion diagnostic-in Vitro diagnostic (CDx-IVD) product in China for Larotrectinib. NTRK gene fusion detection

• The collaboration will begin with the development of a CDx-IVD for larotrectinib for the Chinese market. Larotrectinib is the world’s first TRK inhibitor to be approved in patients with TRK gene fusion cancer in all solid tumors in the United States (2018) and Europe (2019)

• The collaboration aims to develop a kit for China that helps to identify all TRK fusion cancer patients who may benefit from therapy.



Beijing, Shanghai, April 30th, 2020 - Bayer and OrigiMed (Shanghai) Co., Ltd. (referred to as "OrigiMed") today announced a strategic collaboration for the development and commercialization of NGS-based companion diagnostics – in vitro diagnostic (CDx-IVD) in China for detection of NTRK gene fusions. This collaboration will focus on developing a CDx-IVD for larotrectinib (Vitrakvi®) for the Chinese market, the first TRK inhibitor approved in the US (2018) and Europe (2019) for adult and pediatrics with TRK fusion cancer and is currently developed globally, including in China.


"Approved in various markets already including the US and EU, larotrectinib is a first-of-its-kind treatment exclusively designed for adults and children with TRK fusion cancer. It is also the first compound that received it's initial approved based on the molecular alteration (NTRK gene fusion) driving their cancer irrespective of the tumor site of origin," said Dr. Emmanuelle di Tomaso, Head of Oncology Precision Medicine, Bayer's Oncology Strategic Business Unit, "Cancer care is currently undergoing a paradigm shift, and as this new era of precision oncology treatment unfolds, we are continuing our effort of delivering innovative medicines such as larotrectinib, which can provide value to patients and their treating physicians around the world."  


"As one of the first NGS companies to introduce NTRK gene fusion detection in China, we are looking forward to working with Bayer to develop larotrectinib CDx-IVD, jointly support clinical trials of larotrectinib in mainland China and provide therapeutic benefits for more patients." The genomic testing and analysis of cancer patients to determine whether they are suitable for the treatment of larotrectinib is also a very urgent clinical need," said Dr. Wang Kai, CEO of OrigiMed.




About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the significant challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com .



About OrigiMed

OrigiMed is a medical science and technology transforming company and a partner of biopharmaceutical companies, who focuses on developing new technologies and clinical applications to help all types of cancer patients get access to precise treatment and help accelerate biomarker-driven drug development. By carrying out more comprehensive and high-throughput methods, leveraging wholesome bioinformatics analysis and clinical annotation to help match patients to approved targeted therapies, immunotherapies, and clinical trials-giving physicians and patients powerful actionable insights for navigating cancer care, ultimately aiming to fortify the evolution of cancer precision medicine. More information, please visit www.origimed.com


Company:OrigiMed

Website: www.origimed.com

Contact: Amy Huang

Telephone: 86-13052471970

Email: huangj@origimed.com


Haftungsausschluss: Dieser Artikel wurde aus anderen Medien reproduziert. Der Zweck des Nachdrucks besteht darin, mehr Informationen zu vermitteln. Dies bedeutet nicht, dass diese Website ihren Ansichten zustimmt und für ihre Authentizität verantwortlich ist und keine rechtliche Verantwortung trägt. Alle Ressourcen auf dieser Website werden im Internet gesammelt. Der Zweck des Teilens dient nur dem Lernen und Nachschlagen aller. Wenn eine Verletzung des Urheberrechts oder des geistigen Eigentums vorliegt, hinterlassen Sie uns bitte eine Nachricht.
Zurück nach oben
© Urheberrechte 2009-2020 TOM Nachrichtenportal      Kontaktieren Sie Uns   SiteMap